Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors.
Rousseau C, Ruellan AL, Bernardeau K, Kraeber-Bodéré F, Gouard S, Loussouarn D, Saï-Maurel C, Faivre-Chauvet A, Wijdenes J, Barbet J, et al. EJNMMI Res. 2011 Sep 1; 1(1):20. Epub 2011 Sep 1.